Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARCLeandro N. Güttlein(Fundación Instituto Leloir), Osvaldo L. Podhajcer(Fundación Instituto Leloir)Molecular Cancer ResearchDecember 28, 201610.1158/1541-7786.mcr-16-0243-tCited by 24SaveCiteExport RISWatch citationsRelated PapersCross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines|npj Vaccines|2023|8